Youtor
>> YOUR LINK HERE: ___ http://youtube.com/watch?v=FgO9Y71LwB4
Nicole Chu from the University of Ottawa speaks with Dr. Javed Butler. Dr. Javed Butler, MD, MPH, MBA, is the President of the Baylor Scott and White Research Institute, and Senior Vice President and Maxwell A. and Gayle H. Clampitt Endowed Chair at the Baylor Scott and White Health in Dallas, Texas. He is also the Distinguished Professor of Medicine at the University of Mississippi in Jackson, Mississippi. • In this episode, Dr. Butler shares with us the major findings from the recent EMPACT-MI clinical trial and his perspective on the future of heart failure therapies. The EMPACT-MI trial investigated whether a medicine called empagliflozin, a SGLT2 inhibitor, helps to lower the risk of heart failure and death in people had experienced a heart attack (myocardial infarction). • Learn more about the EMPACT-MI clinical trial • https://www.nejm.org/doi/full/10.1056... • 1:35 - Inspiration behind becoming a heart failure physician? • 2:50 - What is Empagliflozin? How does it relate to heart failure? • 4:30 - Major findings from the EMPACT-MI clinical trial? • 6:49 - Future directions of heart failure therapies? • 8:10 - Words of wisdom for early career professionals interested in cardiology?
#############################
